Filing Details

Accession Number:
0001651308-21-000126
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-06-21 16:45:53
Reporting Period:
2021-06-16
Accepted Time:
2021-06-21 16:45:53
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1651308 Beigene Ltd. BGNE Pharmaceutical Preparations (2834) 981209416
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1683913 Jane Huang C/O Mourant Governance Services (Cayman)
94 Solaris Avenue
Camana Bay, Grand Cayman E9 KY1-1108
Cmo, Hematology No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Acquisiton 2021-06-16 25,350 $0.00 304,186 No 4 A Direct
American Depositary Shares Disposition 2021-06-18 469 $325.66 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 A Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Ordinary Shares Share Option (Right to Buy) Acquisiton 2021-06-16 157,196 $0.00 157,196 $26.53
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
157,196 2031-06-15 No 4 A Direct
Footnotes
  1. Represents securities underlying restricted share units. 1/4th of the securities will vest on each anniversary of June 16, 2021, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.
  2. Each American Depositary Share ("ADS") represents 13 Ordinary Shares.
  3. The sale was effected pursuant to a mandatory tax withholding provision in the Reporting Person's restricted share unit award agreement in connection with the vesting of a restricted share unit award previously granted to the Reporting Person. 1/4th of the securities will vest on each anniversary of June 17, 2020, subject to continued service. Unvested securities are subject to accelerated vesting upon certain termination events following a change in control.
  4. The number of securities underlying the option and the exercise price therefor are represented in ordinary shares.
  5. These securities vest over a four-year period as follows: 25% on June 16, 2022, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control.